Cerebrolysin
NootropicFPF 1070 — Synthetic Peptide
Overview
Cerebrolysin is a standardized heterogeneous peptide mixture produced by controlled enzymatic hydrolysis of porcine brain cortex. It contains approximately 85% free amino acids and 15% low-molecular-weight peptide fragments (1–10 kDa) with neurotrophic properties. It is an approved pharmaceutical product in over 50 countries — including Germany (where it was developed, brand name Cerebrolysin by EVER Neuro Pharma), Austria, Russia, China, and across Eastern Europe and Asia — for the treatment of acute ischemic stroke, Alzheimer's disease, traumatic brain injury, and vascular dementia.
Cerebrolysin is **not** a simple blend of known peptides and should not be categorized with vendor-formulated peptide blends. It is a complex pharmaceutical-grade biological product sold as liquid ampoules for intravenous infusion. Research peptide vendors listing it as a "lyophilized" product should be verified carefully, as this differs from the standard pharmaceutical form.
Cerebrolysin is **not FDA-approved** in the United States. Clinical trial results have been mixed, with the CASTA (Cerebrolysin Acute Stroke Treatment in Asia) trial showing neurological scale improvements but also an increased early mortality signal in one analysis — a finding that has driven ongoing regulatory review and scientific debate.
Mechanism of Action
Cerebrolysin's mechanism is multimodal, reflecting its heterogeneous composition:
**Neurotrophic activity:** Peptide fractions in the 1–10 kDa range show BDNF-like, NGF-like, and CNTF-like neurotrophic properties in cell culture assays — stimulating neurite outgrowth, promoting neuronal survival, and supporting synaptic plasticity.
**Anti-apoptotic signaling:** Cerebrolysin activates the PI3K/Akt and ERK/MAPK pro-survival pathways in neurons, reducing caspase-3 activation and mitochondria-mediated apoptosis in ischemic and excitotoxic stress models.
**Amyloid and tau modulation:** In Alzheimer's models, Cerebrolysin reduces amyloid precursor protein processing toward amyloidogenic pathways and attenuates tau hyperphosphorylation — effects proposed to contribute to cognitive stabilization in dementia patients.
**Neuroplasticity:** Increases dendritic density and synaptic marker expression in aged animal brains, potentially supporting cognitive reserve.
Research Dosing
Standard clinical IV infusion protocol used in countries where approved. Cerebrolysin is sold as liquid ampoules (not lyophilized vials) in most markets — vendors listing it as lyophilized should be approached with caution. Not approved by FDA. Approved in Germany, Austria, Russia, China, and ~50 other countries for stroke rehabilitation and dementia.
Research data only. These dosing ranges are derived from published studies, primarily in animal models. This is not medical advice. No peptide discussed on this site is approved for human therapeutic use unless otherwise noted.
Published Studies
Cerebrolysin for acute ischaemic stroke: systematic review and meta-analysis
Ziganshina LE, Abakumova T, Kuchaeva A, et al. — BMJ Open, 2016
Cochrane-style systematic review of Cerebrolysin in acute ischemic stroke, including the CASTA trial. Found statistically significant improvement in global neurological outcome scales; also found increased early death rate in the Cerebrolysin group in one major trial, raising safety questions. Concluded evidence is insufficient for routine recommendation, reflecting ongoing uncertainty about benefit-risk balance in heterogeneous patient populations.
Cerebrolysin in the treatment of vascular dementia: a meta-analysis of clinical trials
Chen N, Yang M, Guo J, et al. — Journal of the Neurological Sciences, 2013
Meta-analysis of controlled trials in vascular dementia showing statistically significant improvements in cognitive assessment scores (MMSE, ADAS-cog) compared to placebo, with acceptable safety profile. Effect sizes were moderate, and trial quality was variable across included studies.
Neuroprotective and neurotrophic effects of Cerebrolysin: a multimodal drug for the treatment of neurodegenerative conditions
Rockenstein E, Desplats P, Ubhi K, et al. — Drugs of Today, 2012
Mechanistic review of Cerebrolysin's multimodal neuroprotective effects: BDNF-like and NGF-like activity from small peptide fractions, reduction of apoptosis, modulation of amyloid precursor protein processing, and attenuation of tau phosphorylation in Alzheimer's models. Positions Cerebrolysin as a multimodal neurotrophic agent distinct from single-target drugs.